Editorial Videos

Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, discuss adapting to the specific needs and considerations of trials with cardiac, neuro, and pulmonary specialties.

Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, talk about ways their company has improved efficiency and accuracy in clinical trials for clients such as NCI designated cancer centers.

Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, provide commentary on current obstacles associated with clinical trials and how their company is addressing them.

In an interview with ACT Editor Andy Studna, Gadi Saarony, CEO, Advarra, offers his thoughts on the status of the pharmaceutical industry improving diversity in clinical trials.

Christian Olsen, VP, Industry Principal of Biologics at Dotmatics, discusses how artificial intelligence along with other technologies are being used to shorten the drug discovery funnel and reduce research costs.

In an interview with ACT editor Andy Studna at SCOPE, Corrigan discusses what YPrime is doing to address challenges in clinical trials and results from the company's recently released eCOA report.

In an interview with ACT editor Andy Studna at SCOPE, Deyle, VP & GM, Clinical Research, Flatiron Health discusses real-world evidence in clinical trials.

In an interview with ACT editor Andy Studna at SCOPE, Young, Chief Science Officer, CluePoints discusses where the industry is currently adopting RBQM and the level of comfort that comes with it.

In an interview with ACT editor Andy Studna at SCOPE, Everhart, MD, FACP, clinical vice president, internal medicine, Signant Health discusses decentralized trials and how they may be increasing site burden.

In an interview with ACT Editor Andy Studna, Jim Reilly, VP, R&D Strategies, Veeva Systems, discusses improving collaborations with research sites and provides an outlook of how the new year looks for clinical trials.

In an interview with ACT Associate Editor Don Tracy, Shubh Goel, Head of Immuno-Oncology and Gastrointestinal Tumors, US Oncology Business Unit, AstraZeneca, provides her thoughts on the success of the trial.

In an interview with ACT editor Andy Studna, Jim Reilly, VP, R&D Strategy, Veeva Systems, discusses ways stakeholders can select the best solutions available in clinical trials.

In an interview with ACT editor, Andy Studna, Lieberman, Executive Director, Conferences (CHI) & Co-Founder, VP, Community and Business Development (ClinEco) discusses the Summit for Clinical Ops Executives (SCOPE) conferences in Europe and the US.

In an interview with ACT editor, Andy Studna, Lieberman, Executive Director, Conferences (CHI) & Co-Founder, VP, Community and Business Development (ClinEco) discusses what ClinEco is and how the need to create it came about.

Sameer Lal, Sr. Vice President, Enterprise Medical Solutions at Indegene discusses their new study 'Reshaping Pharmacovigilance in the Age of AI'

In an interview with ACT editor, Andy Studna, Hesterlee, Chief Research Officer at the Muscular Dystrophy Association discusses a new therapy for Duchenne Muscular Dystrophy, Vamorolone, and what sets it apart from other therapies in the market.

New pre-competitive, disease-agnostic Consortium hopes to optimize advocacy group-industry collaboration to ultimately accelerate the pace of medicines development.

Slope.io CEO Rust Felix Discusses Phase I/II Oncology Sample Management Using Logistical Workflows

Inato Chief Strategy Officer Liz Beatty Discusses Sites that Want to Participate

Anca Copaescu, Founder and CEO of Strategikon Pharma Discusses Clinical Solutions for the Business Operations Side of Clinical Trials

Rob Bohacs, Chief Solutions Officer and Founder, ClinOne Discusses HCP and Patient Clinical Trials Recruitment

Lucille Coassin, Sr. Dir Pharma Partnerships, Current Health Discusses Connected Device Patient Monitoring